Trial Profile
HPV Immunisation Protecting Special Risk Group Patients From Cervical Cancer: 5 Year Follow-up Post-vaccination
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 19 Jun 2017
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary) ; Immunosuppressants
- Indications Cervical cancer; Cervical intraepithelial neoplasia
- Focus Pharmacodynamics
- 28 Aug 2013 New trial record